Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in Cleveland, OH
NPI: 1023075835Primary Practice Location
CLEVELAND CLINIC
9500 Euclid Ave, Cleveland, OH
Primary Employer
Cleveland Clinic
clevelandclinic.org
HQ Phone
Get M.D. Ronald's Phone Numberphone_androidMobile
Get M.D. Ronald's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardOH State Medical License
OH State Medical License
1995 - 2026
FL State Medical License
2016 - 2018
IL State Medical License
1996 - 1999
American Board of Internal Medicine
Internal Medicine
American Board of Internal Medicine
Hematology
American Board of Internal Medicine
Medical Oncology
Cleveland Medical College, Homeopathic
case.edu
Medical School
Until 1993
University of Chicago
Fellowship • Hematology and Medical Oncology
1996 - 1999
Case Western Reserve University/University Hospitals Cleveland Medical Center
Residency • Internal Medicine
1993 - 1996
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 37 | 72 |
| 2 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 33 | 196 |
| 3 | 99215Established patient office or other outpatient, visit typically 40 minutes | 26 | 75 |
Authors: Lawrence Goodnough, Adam Schwarz
Journal: Vox Sang
Lead Sponsor: Leland Metheny
Intervention / Treatment: DRUG: Inotuzumab Ozogamicin
Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Collaborators: National Cancer Institute (NCI), Blood and Marrow Transplant Clinical Trials Network
Intervention / Treatment: DRUG: Cyclophosphamide, DRUG: Bortezomib, DRUG: Mycophenolate mofetil, DRUG: Maraviroc, DRUG: Tacrolimus (ARM with Methotrexate), DRUG: Tacrolimus (ARM with MMF and Cyclophosphamide), DRUG: Methotrexate (ARM with Maraviroc), DRUG: Methotrexate (ARM with Bortezomib)
Lead Sponsor: Masonic Cancer Center, University of Minnesota
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: KIR genotype
